|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||41.56 - 42.36|
|52-week range||37.88 - 53.86|
|Beta (5Y monthly)||0.30|
|PE ratio (TTM)||20.39|
|Forward dividend & yield||1.24 (3.18%)|
|Ex-dividend date||17 Mar 2022|
|1y target est||51.25|
The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study.
Exelixis (EXEL) starts the phase III STELLAR-303 study evaluating XL092 in combination with atezolizumab as compared to regorafenib for treating patients with metastatic colorectal cancer.
Lilly, Merck, Roche, Pfizer and Moderna have been included in this Analyst Blog.